Association Between Renal Reserve Function and Progression of Renal Function to Predict CKD Risk in Thai Elderly

December 2, 2021 updated by: Kearkiat Praditpornsilpa, Chulalongkorn University

Study of the Association Between Renal Reserve Function and Progression of Renal Function to Predict Chronic Kidney Disease Risk in Thai Elderly

This study investigates renal functional reserve in elderly.

Study Overview

Status

Recruiting

Detailed Description

The prevalence of CKD in elder is high as age has been a variable in eGFR equation. eGFR by calculation always declines in parallel with age. The assumption that a persistent over 3 months of eGFR less than 60 mL/min/1.73m2 define CKD with risk of progression and need refer to nephrologist may not necessary true in aging population. We study renal functional reserve in elderly population who risk of CKD progression and ESRD is the highest prevalence in human life cycle and explore whether renal functional reserve can be used as ad additional marker of CKD progression in elderly.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bangkok, Thailand, 10330
        • Recruiting
        • Kearkiat Praditpornsilpa
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Elders age more than 60 years who are non-frail and has no limited life expectancy

Description

Inclusion Criteria:

  • Patient age > 60 years at screening
  • Patient willing to participate in the study and can provide inform consent
  • Patient have residual kidney function ≤ 90 ml/min/1.73m2 by CKD-EPI equation

Exclusion Criteria:

  • Patient active smoking
  • Patient have Charlson comorbidity index > .....
  • Patient active cancer
  • Patient contraindications for blood collection
  • Patients with a history of hypersensitivity to cimetidine or amino acid IV solution

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of renal functional reserve per 12 months (mL/min)
Time Frame: 12 months
Renal functional reserve defined as the difference between baseline creatinine clearance and creatinine clearance achieved under stimulation with amino acid infusion.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 24, 2019

Primary Completion (Anticipated)

June 30, 2022

Study Completion (Anticipated)

December 30, 2022

Study Registration Dates

First Submitted

December 2, 2021

First Submitted That Met QC Criteria

December 2, 2021

First Posted (Actual)

December 15, 2021

Study Record Updates

Last Update Posted (Actual)

December 15, 2021

Last Update Submitted That Met QC Criteria

December 2, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • IRB NO.527/62

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Function Abnormal

Subscribe